| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus | 44 | 2020 | 79 | 5.140 |
Why?
|
| Cytomegalovirus Infections | 30 | 2020 | 82 | 4.250 |
Why?
|
| DNA, Viral | 22 | 2020 | 98 | 1.660 |
Why?
|
| Antiviral Agents | 19 | 2020 | 136 | 1.230 |
Why?
|
| HIV Infections | 12 | 2020 | 997 | 1.150 |
Why?
|
| HIV-1 | 6 | 2015 | 451 | 1.030 |
Why?
|
| Viral Load | 10 | 2018 | 208 | 1.000 |
Why?
|
| Drug Resistance, Viral | 8 | 2014 | 40 | 0.860 |
Why?
|
| Ganciclovir | 15 | 2014 | 27 | 0.770 |
Why?
|
| Antibodies, Viral | 7 | 2018 | 89 | 0.660 |
Why?
|
| Viral Proteins | 9 | 2011 | 24 | 0.620 |
Why?
|
| Cervix Uteri | 5 | 2015 | 40 | 0.590 |
Why?
|
| Coinfection | 1 | 2015 | 29 | 0.510 |
Why?
|
| Immunoglobulin G | 5 | 2018 | 129 | 0.510 |
Why?
|
| Humans | 59 | 2020 | 29845 | 0.460 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2010 | 14 | 0.440 |
Why?
|
| Polymerase Chain Reaction | 6 | 2011 | 166 | 0.430 |
Why?
|
| Viremia | 4 | 2015 | 37 | 0.410 |
Why?
|
| Antigens, CD | 4 | 2015 | 102 | 0.400 |
Why?
|
| Alzheimer Disease | 2 | 2013 | 2005 | 0.390 |
Why?
|
| Hepatitis B virus | 1 | 2011 | 7 | 0.390 |
Why?
|
| Hepatitis B | 1 | 2011 | 18 | 0.390 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 48 | 0.390 |
Why?
|
| Genome, Viral | 3 | 2010 | 12 | 0.380 |
Why?
|
| DNA-Directed DNA Polymerase | 8 | 2010 | 9 | 0.360 |
Why?
|
| Lung Transplantation | 4 | 2014 | 18 | 0.340 |
Why?
|
| Receptors, Cell Surface | 3 | 2015 | 50 | 0.330 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2007 | 19 | 0.300 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 13 | 0.290 |
Why?
|
| Female | 24 | 2020 | 16426 | 0.290 |
Why?
|
| Membrane Glycoproteins | 4 | 2005 | 103 | 0.280 |
Why?
|
| Organ Transplantation | 3 | 2010 | 37 | 0.280 |
Why?
|
| Virology | 1 | 2006 | 15 | 0.270 |
Why?
|
| Molecular Sequence Data | 8 | 2006 | 248 | 0.270 |
Why?
|
| Viral Envelope Proteins | 4 | 2020 | 22 | 0.270 |
Why?
|
| Drug Resistance, Microbial | 9 | 2002 | 96 | 0.270 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 5 | 0.270 |
Why?
|
| Reproducibility of Results | 6 | 2011 | 803 | 0.270 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2015 | 16 | 0.270 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2015 | 27 | 0.270 |
Why?
|
| Interferon-gamma | 3 | 2015 | 111 | 0.260 |
Why?
|
| T-Lymphocytes | 4 | 2013 | 224 | 0.260 |
Why?
|
| Hepacivirus | 1 | 2006 | 75 | 0.260 |
Why?
|
| Genital Diseases, Female | 1 | 2004 | 10 | 0.240 |
Why?
|
| Mutation | 8 | 2009 | 399 | 0.240 |
Why?
|
| Base Sequence | 7 | 2009 | 135 | 0.240 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2016 | 110 | 0.230 |
Why?
|
| Foscarnet | 8 | 2010 | 8 | 0.230 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 196 | 0.220 |
Why?
|
| Genes, Viral | 4 | 2016 | 10 | 0.220 |
Why?
|
| Virus Replication | 7 | 2020 | 92 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 2 | 2020 | 14 | 0.210 |
Why?
|
| RNA, Viral | 5 | 2016 | 159 | 0.210 |
Why?
|
| Leukocytes | 2 | 2015 | 45 | 0.200 |
Why?
|
| Fibroblasts | 5 | 2013 | 93 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2015 | 109 | 0.200 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 558 | 0.200 |
Why?
|
| Carotid Artery Diseases | 2 | 2012 | 44 | 0.190 |
Why?
|
| Genotype | 5 | 2006 | 408 | 0.190 |
Why?
|
| Adult | 13 | 2020 | 8746 | 0.190 |
Why?
|
| Male | 17 | 2020 | 15868 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 19 | 0.180 |
Why?
|
| DNA Virus Infections | 1 | 2020 | 5 | 0.180 |
Why?
|
| RNA Virus Infections | 1 | 2020 | 5 | 0.180 |
Why?
|
| RNA Viruses | 1 | 2020 | 5 | 0.180 |
Why?
|
| Salicylates | 1 | 2020 | 7 | 0.180 |
Why?
|
| DNA Viruses | 1 | 2020 | 6 | 0.180 |
Why?
|
| Isoxazoles | 3 | 2010 | 16 | 0.180 |
Why?
|
| Viral Fusion Proteins | 1 | 2020 | 16 | 0.180 |
Why?
|
| Lymphocyte Activation | 3 | 2013 | 215 | 0.180 |
Why?
|
| Receptors, Immunologic | 2 | 2013 | 34 | 0.180 |
Why?
|
| Hepatitis C | 2 | 2013 | 66 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2018 | 19 | 0.160 |
Why?
|
| Anti-HIV Agents | 2 | 2018 | 173 | 0.160 |
Why?
|
| Inflammation | 3 | 2015 | 347 | 0.150 |
Why?
|
| Cytosine | 2 | 2010 | 6 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2011 | 46 | 0.150 |
Why?
|
| Middle Aged | 11 | 2020 | 9960 | 0.150 |
Why?
|
| Strophanthins | 1 | 2016 | 1 | 0.140 |
Why?
|
| Methionine | 1 | 2016 | 3 | 0.140 |
Why?
|
| Carotid Arteries | 3 | 2012 | 54 | 0.140 |
Why?
|
| Open Reading Frames | 3 | 2006 | 12 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 3 | 2013 | 3 | 0.140 |
Why?
|
| Cells, Cultured | 7 | 2015 | 682 | 0.140 |
Why?
|
| Biomarkers | 2 | 2018 | 704 | 0.130 |
Why?
|
| Tissue Donors | 1 | 1996 | 73 | 0.130 |
Why?
|
| Raltegravir Potassium | 1 | 2015 | 9 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2009 | 110 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 155 | 0.130 |
Why?
|
| Sulfates | 1 | 2015 | 16 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2015 | 27 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2015 | 14 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 21 | 0.130 |
Why?
|
| Interleukins | 1 | 2015 | 37 | 0.130 |
Why?
|
| Indoles | 1 | 2015 | 51 | 0.130 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 52 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 1999 | 45 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2008 | 92 | 0.120 |
Why?
|
| Cell Line | 5 | 2016 | 299 | 0.120 |
Why?
|
| Organ Culture Techniques | 3 | 2011 | 29 | 0.120 |
Why?
|
| Point Mutation | 1 | 1994 | 30 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2018 | 1953 | 0.110 |
Why?
|
| Viral Structural Proteins | 1 | 1992 | 4 | 0.110 |
Why?
|
| Organophosphonates | 2 | 2010 | 5 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 19 | 0.110 |
Why?
|
| Phylogeny | 3 | 2005 | 63 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2005 | 33 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 88 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 93 | 0.110 |
Why?
|
| Neurofibrillary Tangles | 1 | 2013 | 189 | 0.100 |
Why?
|
| Decidua | 1 | 2011 | 1 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2011 | 19 | 0.100 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 135 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2013 | 223 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 3 | 1999 | 16 | 0.100 |
Why?
|
| Plasma | 1 | 2011 | 34 | 0.100 |
Why?
|
| Vascular Stiffness | 1 | 2011 | 9 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 302 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 146 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 18 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 34 | 0.090 |
Why?
|
| Genes, Reporter | 2 | 2008 | 29 | 0.090 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 30 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2007 | 32 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 74 | 0.090 |
Why?
|
| Toll-Like Receptors | 2 | 2007 | 27 | 0.090 |
Why?
|
| Gene Expression | 4 | 2011 | 232 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 63 | 0.080 |
Why?
|
| Artemisinins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Skin | 2 | 2003 | 118 | 0.080 |
Why?
|
| Betaherpesvirinae | 1 | 2008 | 1 | 0.080 |
Why?
|
| Virion | 2 | 2020 | 13 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 21 | 0.080 |
Why?
|
| Foreskin | 1 | 2007 | 1 | 0.080 |
Why?
|
| Poly I-C | 1 | 2007 | 6 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2007 | 7 | 0.080 |
Why?
|
| Receptors, Virus | 2 | 2005 | 7 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 3 | 0.080 |
Why?
|
| HIV Core Protein p24 | 1 | 2007 | 29 | 0.080 |
Why?
|
| Culture Media | 1 | 2007 | 36 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 129 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2007 | 36 | 0.070 |
Why?
|
| Phenotype | 3 | 2003 | 364 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2007 | 65 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 69 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1986 | 11 | 0.070 |
Why?
|
| Laboratories | 1 | 2006 | 26 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2006 | 7 | 0.070 |
Why?
|
| Glycosylation | 1 | 2006 | 24 | 0.070 |
Why?
|
| Herpesviridae | 1 | 2005 | 2 | 0.070 |
Why?
|
| Vaginosis, Bacterial | 1 | 2005 | 31 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 160 | 0.060 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2004 | 1 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2004 | 1 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 66 | 0.060 |
Why?
|
| Saliva | 1 | 2004 | 54 | 0.060 |
Why?
|
| Vagina | 1 | 2004 | 49 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1992 | 132 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2003 | 23 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 4930 | 0.060 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2003 | 4 | 0.060 |
Why?
|
| Aged | 2 | 2014 | 9619 | 0.050 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 9 | 0.050 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 159 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 643 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2015 | 202 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 26 | 0.050 |
Why?
|
| Models, Biological | 2 | 2015 | 347 | 0.050 |
Why?
|
| CD57 Antigens | 2 | 2011 | 5 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2011 | 18 | 0.050 |
Why?
|
| HLA-DR Antigens | 2 | 2011 | 26 | 0.050 |
Why?
|
| CD28 Antigens | 2 | 2011 | 18 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2016 | 325 | 0.050 |
Why?
|
| Animals | 3 | 2020 | 4639 | 0.050 |
Why?
|
| Vero Cells | 1 | 2020 | 7 | 0.050 |
Why?
|
| DNA Replication | 1 | 2020 | 12 | 0.050 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2013 | 2 | 0.040 |
Why?
|
| Virus Internalization | 1 | 2020 | 17 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 98 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 2466 | 0.040 |
Why?
|
| Astrocytes | 1 | 2020 | 122 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 456 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2018 | 81 | 0.040 |
Why?
|
| Mucous Membrane | 2 | 2009 | 40 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2013 | 491 | 0.040 |
Why?
|
| Cardiac Glycosides | 1 | 2016 | 1 | 0.040 |
Why?
|
| Genes, Immediate-Early | 1 | 2016 | 2 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 2016 | 18 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2016 | 28 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 43 | 0.040 |
Why?
|
| Time Factors | 3 | 2011 | 1641 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1996 | 5 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 1996 | 22 | 0.040 |
Why?
|
| DNA Primers | 1 | 1996 | 54 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2016 | 82 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 37 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2002 | 957 | 0.030 |
Why?
|
| Complement Inactivator Proteins | 1 | 1995 | 1 | 0.030 |
Why?
|
| CD55 Antigens | 1 | 1995 | 2 | 0.030 |
Why?
|
| CD59 Antigens | 1 | 1995 | 3 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1995 | 12 | 0.030 |
Why?
|
| Immunization | 1 | 2015 | 47 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 854 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 31 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 42 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 85 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 165 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 266 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 969 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2015 | 150 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2015 | 90 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1994 | 7 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2010 | 685 | 0.030 |
Why?
|
| Simplexvirus | 2 | 1999 | 9 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 8 | 0.030 |
Why?
|
| Lymphotoxin-alpha | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 22 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 26 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2013 | 19 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3560 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2013 | 68 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 112 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 33 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 78 | 0.030 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1992 | 7 | 0.030 |
Why?
|
| Plasmids | 1 | 1992 | 44 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 55 | 0.030 |
Why?
|
| Transfection | 1 | 1992 | 130 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 95 | 0.030 |
Why?
|
| Antigens, Viral | 3 | 1998 | 19 | 0.030 |
Why?
|
| Tunica Intima | 1 | 2012 | 27 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2011 | 18 | 0.020 |
Why?
|
| Fetal Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 7 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 133 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 494 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2010 | 37 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 387 | 0.020 |
Why?
|
| Palatine Tonsil | 1 | 2009 | 7 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 174 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 223 | 0.020 |
Why?
|
| Rectum | 1 | 2009 | 61 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 215 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 224 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 1999 | 64 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 1969 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2010 | 3324 | 0.020 |
Why?
|
| Virus Shedding | 1 | 2007 | 15 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 58 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2008 | 110 | 0.020 |
Why?
|
| Deoxyribonuclease BamHI | 1 | 1986 | 1 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1986 | 4 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2005 | 2 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 29 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1824 | 0.020 |
Why?
|
| Binding Sites | 1 | 2005 | 76 | 0.020 |
Why?
|
| Immunity, Mucosal | 1 | 2005 | 29 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2005 | 32 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2005 | 33 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2004 | 11 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 13 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2004 | 8 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2004 | 60 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 273 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 58 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 177 | 0.010 |
Why?
|
| Child | 1 | 2008 | 1379 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 92 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 4 | 0.010 |
Why?
|
| Infant | 1 | 2004 | 541 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 94 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 142 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 58 | 0.010 |
Why?
|
| Viral Plaque Assay | 2 | 1992 | 2 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2002 | 75 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 98 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 231 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 245 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 376 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 279 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1999 | 3 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1999 | 27 | 0.010 |
Why?
|
| Codon | 1 | 1999 | 8 | 0.010 |
Why?
|
| Virulence | 1 | 1999 | 15 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 107 | 0.010 |
Why?
|
| Uridine | 1 | 1999 | 2 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 12 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 6 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 1857 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 877 | 0.010 |
Why?
|
| Phosphonoacetic Acid | 1 | 1992 | 1 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1991 | 34 | 0.010 |
Why?
|